Display options
Share it on

United European Gastroenterol J. 2017 Aug;5(5):715-724. doi: 10.1177/2050640616684398. Epub 2016 Dec 11.

Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of .

United European gastroenterology journal

Fabio Turco, Paolo Andreozzi, Ilaria Palumbo, Francesco Paolo Zito, Martina Cargiolli, Walter Fiore, Nicola Gennarelli, Giovanni Domenico De Palma, Giovanni Sarnelli, Rosario Cuomo

Affiliations

  1. Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
  2. Sofar S.p.A. Trezzano Rosa, Italy.

PMID: 28815036 PMCID: PMC5548353 DOI: 10.1177/2050640616684398

Abstract

BACKGROUND: Micro-inflammation and changes in gut microbiota may play a role in the pathogenesis of diverticular disease (DD).

OBJECTIVE: The objective of this article is to evaluate the expression of nitric oxide (NO)-related mediators and S100B in colonic mucosa of patients with DD in an ex vivo model of bacterial infection.

METHODS: Intestinal biopsies obtained from patients with diverticulosis, symptomatic uncomplicated diverticular disease (SUDD) and SUDD with previous acute diverticulitis (SUDD+AD) were stimulated with the probiotic

RESULTS: Basal iNOS expression was significantly increased in SUDD and SUDD+AD patients. Basal NO expression was significantly increased in SUDD+AD. No differences in S100B release were found. In all groups, iNOS expression was significantly increased by EIEC and reduced by LCDG. In all groups, except for SUDD+AD, EIEC significantly increased NO release, whereas no increase was observed when LCDG was added to biopsies. EIEC did not induce significant changes in S100B release.

CONCLUSIONS: Colonic mucosa of patients with DD is characterized by a different reactivity toward pathogenic stimuli. LCDG plays a role in counteracting the pro-inflammatory effects exerted by EIEC, suggesting a beneficial role of this probiotic in DD.

Keywords: Diverticular disease; enteroinvasive Escherichia coli; human colonic mucosa; nitric oxide; probiotic

References

  1. Neurogastroenterol Motil. 2014 Oct;26(10 ):1458-68 - PubMed
  2. Mol Med. 2000 May;6(5):347-73 - PubMed
  3. Neurogastroenterol Motil. 2009 Nov;21(11):1209-e112 - PubMed
  4. Expert Opin Pharmacother. 2007 Feb;8(3):299-307 - PubMed
  5. J Clin Gastroenterol. 2008 Jul;42(6):699-703 - PubMed
  6. Clin Microbiol Rev. 1998 Jan;11(1):142-201 - PubMed
  7. Biochem Biophys Res Commun. 1988 Nov 30;157(1):87-94 - PubMed
  8. Gastroenterology. 1992 Feb;102(2):679-83 - PubMed
  9. J Clin Pathol. 2005 Sep;58(9):973-7 - PubMed
  10. World J Gastroenterol. 2009 May 28;15(20):2479-88 - PubMed
  11. Neurogastroenterol Motil. 2011 Sep;23(9):e372-82 - PubMed
  12. Neurogastroenterol Motil. 2010 Apr;22(4):407-14, e93-4 - PubMed
  13. Colorectal Dis. 2007 Mar;9(3):218-28 - PubMed
  14. Inflamm Bowel Dis. 2016 Feb;22(2):433-49 - PubMed
  15. Int J Surg. 2014;12(5):426-31 - PubMed
  16. Scand J Gastroenterol. 1977;12 (7):857-64 - PubMed
  17. United European Gastroenterol J. 2014 Oct;2(5):413-42 - PubMed
  18. Br J Surg. 1962 Sep;50:185-90 - PubMed
  19. Gastroenterology. 2007 Sep;133(3):918-25 - PubMed
  20. Aliment Pharmacol Ther. 2013 Oct;38(7):741-51 - PubMed
  21. Gastroenterology. 2009 Apr;136(4):1134-44 - PubMed
  22. Gut. 1988 Feb;29(2):218-22 - PubMed
  23. Biochem Biophys Res Commun. 1990 Nov 15;172(3):1246-52 - PubMed
  24. Dig Dis Sci. 2011 Apr;56(4):1178-87 - PubMed
  25. Am J Gastroenterol. 2012 Oct;107(10):1486-93 - PubMed
  26. Dis Colon Rectum. 2011 Oct;54(10):1326-38 - PubMed
  27. Gut. 2014 Jan;63(1):105-15 - PubMed
  28. Mucosal Immunol. 2017 Jan;10 (1):18-26 - PubMed
  29. Neurogastroenterol Motil. 2015 Mar;27(3):305-12 - PubMed

Publication Types